DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 01:42:18 2024-06-14 pm EDT | ||
| 1.09 EUR | +3.81% |
|
| 1 month | +28.24% | ||
| 3 months | +22.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 1.09 | +3.81% |
| 24-06-13 | 1.05 | -2.78% |
| 24-06-12 | 1.08 | +1.89% |
| 24-06-11 | 1.06 | -2.75% |
| 24-06-10 | 1.09 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:42 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM51T1 |
| ISIN | DE000VM51T14 |
| Date issued | 2023-11-27 |
| Strike | 130 $ |
| Maturity | 2024-12-20 (188 Days) |
| Parity | 10 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.1 € |
|---|---|
| Lowest since issue | 0.24 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
